Growth Metrics

Catheter Precision (VTAK) Long-Term Deferred Tax (2022 - 2023)

Catheter Precision (VTAK) reported Long-Term Deferred Tax of $26.8 million for Q4 2023, up 207.88% year-over-year from $8.7 million in Q4 2022, and up 207.88% on a QoQ basis from $8.7 million in Q4 2022.

Catheter Precision (VTAK) has 2 years of Long-Term Deferred Tax data on file, last reported at $26.8 million in Q4 2023.

  • Quarterly Long-Term Deferred Tax rose 207.88% year-over-year to $26.8 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $26.8 million (up 207.88% YoY) and the FY2023 annual result came in at $26.8 million, up 207.88% from the prior year.
  • Long-Term Deferred Tax grew to $26.8 million in Q4 2023 per VTAK's latest filing, from $8.7 million in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $26.8 million in Q4 2023 and bottomed at $8.7 million in Q4 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 Catheter Precision 2.01 Mn 1.20 Mn 390,000.00

Historic Data

Download Data 🔒
DateValue
Dec 31, 2023 26.77 Mn
Dec 31, 2022 8.69 Mn